DALLAS / Jul 09, 2024 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the second quarter ended June 30, 2024, on Aug. 6, 2024, and host a webcast and conference call on Aug. 7, 2024. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time.
A link to the webcast of the conference call and online replay can be found on Enhabit’s investor website.
About Enhabit Home Health & Hospice
Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.
| Last Trade: | US$8.11 |
| Daily Change: | 0.05 0.62 |
| Daily Volume: | 380,795 |
| Market Cap: | US$411.100M |
August 06, 2025 May 07, 2025 November 06, 2024 August 06, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
